Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.
Advertisement

Related Content

Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
Replagal Advisory Committee Will Include Closed Door Session On Manufacturing
TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
Shire Anticipates Vyvanse Approval “Any Day”
Shire Specialty Pharmaceuticals President Mike Cola: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Shire Submits Elaprase BLA For Hunter Syndrome
Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
Adderall XR Sales Rebounding, Shire Says
TKT Hopes To "Break Even" In 2006 Following Hunter Syndrome Therapy BLA
TKT Hopes To "Break Even" In 2006 Following Hunter Syndrome Therapy BLA

Topics

Advertisement
UsernamePublicRestriction

Register

PS062053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel